Article

Low sex hormone levels increase fracture risk in older men

Meier C, Nguyen TV, Handelsman DJ, et al, University Hospital Basel, Switzerland, andother centers. Endogenous sex hormones and incident fracture risk in older men: theDubbo Osteoporosis Epidemiology Study. Arch Intern Med. 2008;168:47-54.

 

Low serum levels of testosterone and estradiol (E2) are associated with an increased osteoporotic fracture risk in community dwelling men older than 60 years, although only the effect of testosterone is associated independent of other established risk factors. Measurement of serum testosterone may provide additional clinical information for fracture risk assessment in these men.

Meier and colleagues prospectively examined the relationship between serum levels of testosterone and E2 and future fracture risk in 609 men (mean age, 72.6 years). They assessed lifestyle factors, calcium intake, and bone mineral density (BMD); determined the incidence of low-trauma fracture; and measured serum testosterone and E2 levels by tandem mass spectrometry.

During follow-up, the incidence of fracture was 2.7-fold higher in men 70 years or older than in younger men. The risk of fracture was increased significantly in men with lower testosterone levels. Serum testosterone and serum E2 levels were associated with overall fracture risk after adjustment for sex hormone–binding globulin. After further adjustment for major risk factors (eg, age,weight or BMD, and fracture history), a lower testosterone level was still associated with increased risk of fracture.

The authors noted that their findings should not be interpreted as an indication of a causal relationship.

Related Videos
John Stone, MD, MPH: Continuing Progress With IgG4-Related Disease Research
Philip Conaghan, MBBS, PhD: Investigating NT3 Inhibition for Improving Osteoarthritis
Rheumatologists Recognize the Need to Create Pediatric Enthesitis Scoring Tool
Presence of Diffuse Cutaneous Disease Linked to Worse HRQOL in Systematic Sclerosis
Alexei Grom, MD: Exploring Safer Treatment Options for Refractory Macrophage Activation Syndrome
Jack Arnold, MBBS, clinical research fellow, University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine
John Tesser, MD, Adjunct Assistant Professor of Medicine, Midwestern University, and Arizona College of Osteopathic Medicine, and Lecturer, University of Arizona Health Sciences Center, and Arizona Arthritis & Rheumatology Associates
Gaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
© 2024 MJH Life Sciences

All rights reserved.